Weekly gemcitabine (GEM) and 5-fluorouracil (5-FU) in pancreatic carcinoma. Phase I–II study

Tarantini, Paola; Corsi, D.C.; Cassano, Alessandra; Pozzo, C.; Angelelli, Lucia; Signorelli, Carlo; Specchia, ML; Barone, C.

doi:10.1016/s0959-8049(99)81010-7

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this small series, no WHO Grade 3 or 4 toxicities were observed. Moreover, the interim median overall survival was 13 months, compared with only 7 months and 4.4 months, respectively, in the trials by Cascinu et al31 and Berlin et al32 The ongoing trial of Tarantini et al,35 using escalating doses of both gemcitabine and 5‐FU, achieved a PR in four patients and a high rate of CBR, but was associated with high levels of toxicity (Table 1).…”

Section: Gemcitabine With Bolus 5‐fumentioning

confidence: 95%

“…To date, there is a wealth of published reports of Phase I‐II trials of gemcitabine in combination with 5‐FU with or without FA for the treatment of patients with advanced pancreatic cancer (Tables 1 and 2). Although the dose and schedule of administration of gemcitabine has been similar in nearly all the trials, the administration of 5‐FU varies from protracted continuous infusion to 24‐hour continuous infusion to weekly bolus infusion at differing dose levels with16–24 or without FA 25–35. In five fully completed trials,16, 17, 25, 31, 32 four different treatment schedules for 5‐FU were used.…”

Section: Gemcitabine In Combination With 5‐fumentioning

confidence: 99%

“…All these trials,25, 31, 32, 35 regardless of drug doses and schedule of administration, reported improved therapeutic outcomes compared with gemcitabine monotherapy,10–13 5‐FU monotherapy,2 or biomodulated 5‐FU therapy 3…”

Section: Gemcitabine In Combination With 5‐fu and Famentioning

confidence: 99%

See 2 more Smart Citations

Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer

Oettle

Riess

2002

Cancer

View full text Add to dashboard Cite

show abstract

Section: Gemcitabine With Bolus 5‐fumentioning

confidence: 95%

Section: Gemcitabine In Combination With 5‐fumentioning

confidence: 99%

See 1 more Smart Citation

Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer

Oettle

Riess

2002

Cancer

View full text Add to dashboard Cite

show abstract

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer

Ward

Morris²,

Bansback³

et al. 2001

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Rapid reviews are completed in a limited time to inform the appraisal and guideline development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidelines produced by NICE are informed by a wide range of sources.The research reported in this monograph was funded as project number 00/10/01.The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors.Criteria for inclusion in the HTA monograph series Reports are pu...

show abstract

Weekly gemcitabine (GEM) and 5-fluorouracil (5-FU) in pancreatic carcinoma. Phase I–II study

Cited by 2 publications

References 0 publications

Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer

Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer

Contact Info

Product

Resources

About